Literature DB >> 21301324

Modest abuse-related subjective effects of zolpidem in drug-naive volunteers.

Stephanie C Licata1, Yasmin Mashhoon, Robert R Maclean, Scott E Lukas.   

Abstract

Recent case reports suggest that the short-acting benzodiazepine-like hypnotic, zolpidem, may have abuse potential among individuals who have no personal history of abusing drugs or alcohol, particularly at doses higher than those recommended for treating insomnia. This study recruited drug-naive volunteers to assess the subjective effects of multiple doses of zolpidem (0, 5, 10, or 20 mg) administered in a within-subject double-blind design. Participants (n=11) answered computerized questionnaires (Addiction Research Center Inventory, visual analog scales, and a hypothetical Drug versus Money Choice) to address the hypothesis that a supratherapeutic dose (20 mg) would increase ratings of abuse-related subjective effects, while lower therapeutic doses (5 and 10 mg) would not. Although participants rated some effects as negative at 10 and 20 mg, the highest dose engendered predominantly positive abuse-like effects such as 'High', 'Like', and 'Good Effects'. However, no dose of zolpidem was chosen over money ($0.35-$10) when participants made hypothetical choices between them. Results suggest that although individuals without a drug abuse history are not inclined to choose zolpidem when presented with an alternative reinforcer such as money, it may possess moderate abuse potential that limits its clinical utility.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301324      PMCID: PMC3077937          DOI: 10.1097/FBP.0b013e328343d78a

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  45 in total

1.  Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.

Authors:  C R Rush; R R Griffiths
Journal:  J Clin Psychopharmacol       Date:  1996-04       Impact factor: 3.153

2.  Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.

Authors:  James K Rowlett; Snjezana Lelas; Walter Tornatzky; Stephanie C Licata
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

3.  Extensive craving in high dose zolpidem dependency.

Authors:  Jana Svitek; Annemarie Heberlein; Stefan Bleich; Jens Wiltfang; Johannes Kornhuber; Thomas Hillemacher
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-11-12       Impact factor: 5.067

4.  Dependence on zolpidem.

Authors:  Ming-Chyi Huang; Hong-Yen Lin; Chun-Hsin Chen
Journal:  Psychiatry Clin Neurosci       Date:  2007-04       Impact factor: 5.188

5.  Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans.

Authors:  C R Rush; R W Baker; K Wright
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

Review 6.  Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.

Authors:  R R Griffiths; E M Weerts
Journal:  Psychopharmacology (Berl)       Date:  1997-11       Impact factor: 4.530

7.  The antinociceptive effect of zolpidem and zopiclone in mice.

Authors:  Chaim G Pick; Yakov Chernes; Tova Rigai; Kenner C Rice; Shaul Schreiber
Journal:  Pharmacol Biochem Behav       Date:  2005-07       Impact factor: 3.533

Review 8.  Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data.

Authors:  G Hajak; W E Müller; H U Wittchen; D Pittrow; W Kirch
Journal:  Addiction       Date:  2003-10       Impact factor: 6.526

Review 9.  Anxious depression: clinical features and treatment.

Authors:  Sanjai Rao; Sidney Zisook
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

10.  Modafinil and zolpidem use by emergency medicine residents.

Authors:  Brian D McBeth; Robert M McNamara; Felix K Ankel; Emily J Mason; Louis J Ling; Thomas J Flottemesch; Brent R Asplin
Journal:  Acad Emerg Med       Date:  2009-12       Impact factor: 3.451

View more
  9 in total

Review 1.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

2.  Zolpidem reduces the blood oxygen level-dependent signal during visual system stimulation.

Authors:  Stephanie C Licata; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-30       Impact factor: 5.067

3.  The hypnotic zolpidem increases the synchrony of BOLD signal fluctuations in widespread brain networks during a resting paradigm.

Authors:  Stephanie C Licata; Lisa D Nickerson; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas
Journal:  Neuroimage       Date:  2013-01-05       Impact factor: 6.556

4.  Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward.

Authors:  Lauren M Reynolds; Elif Engin; Gabriella Tantillo; Hew Mun Lau; John W Muschamp; William A Carlezon; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

Review 5.  Zolpidem: Efficacy and Side Effects for Insomnia.

Authors:  Amber N Edinoff; Natalie Wu; Yahya T Ghaffar; Rosemary Prejean; Rachel Gremillion; Mark Cogburn; Azem A Chami; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

6.  Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.

Authors:  Elif Engin; Konstantin I Bakhurin; Kiersten S Smith; Rochelle M Hines; Lauren M Reynolds; Wannan Tang; Rolf Sprengel; Stephen J Moss; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2014-02-19       Impact factor: 7.853

7.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

8.  Polysomnographic Sleep Disturbances Due to High-Dose Zolpidem Use: A Case Report.

Authors:  Hayato Ohshima; Nozomu Kotorii; Minoru Takii; Hiroshi Hiejima; Mitsunari Habukawa; Hiroo Kuwahara; Naohisa Uchimura
Journal:  J Clin Sleep Med       Date:  2018-11-15       Impact factor: 4.062

9.  High-dose zolpidem dependence - Psychostimulant effects? A case report and literature review.

Authors:  Abhijna Chandan Chattopadhyay; Lekhansh Shukla; Arun Kandasamy; Vivek Benegal
Journal:  Ind Psychiatry J       Date:  2016 Jul-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.